COSCIENS Biopharma Inc.
CSCI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $13,783 | $7,143 | $14,572 | $13,486 |
| % Growth | 93% | -51% | 8.1% | – |
| Cost of Goods Sold | $6,984 | $4,205 | $6,016 | $5,277 |
| Gross Profit | $6,799 | $2,938 | $8,556 | $8,210 |
| % Margin | 49.3% | 41.1% | 58.7% | 60.9% |
| R&D Expenses | $8,304 | $2,040 | $1,371 | $3,042 |
| G&A Expenses | $10,448 | $5,593 | $2,727 | $2,541 |
| SG&A Expenses | $10,448 | $5,527 | $2,865 | $2,578 |
| Sales & Mktg Exp. | $0 | $31 | $22 | $37 |
| Other Operating Expenses | $14,328 | $0 | $0 | $162 |
| Operating Expenses | $33,080 | $7,567 | $4,236 | $5,782 |
| Operating Income | -$26,281 | -$4,629 | $4,320 | $2,428 |
| % Margin | -190.7% | -64.8% | 29.6% | 18% |
| Other Income/Exp. Net | $11,056 | $259 | $208 | $159 |
| Pre-Tax Income | -$15,225 | -$4,370 | $4,528 | $2,587 |
| Tax Expense | $84 | -$885 | $1,080 | -$53 |
| Net Income | -$15,309 | -$3,485 | $3,448 | $2,640 |
| % Margin | -111.1% | -48.8% | 23.7% | 19.6% |
| EPS | -5.93 | -1.89 | 2.51 | 1.69 |
| % Growth | -213.8% | -175.3% | 48.5% | – |
| EPS Diluted | -5.93 | -1.89 | 2.5 | 1.69 |
| Weighted Avg Shares Out | 2,581 | 1,847 | 1,840 | 1,833 |
| Weighted Avg Shares Out Dil | 2,581 | 1,847 | 1,855 | 1,855 |
| Supplemental Information | – | – | – | – |
| Interest Income | $441 | $59 | $145 | $0 |
| Interest Expense | $129 | $136 | $143 | $119 |
| Depreciation & Amortization | $1,607 | $1,443 | $1,468 | $1,475 |
| EBITDA | -$13,489 | -$2,791 | $6,139 | $4,181 |
| % Margin | -97.9% | -39.1% | 42.1% | 31% |